St. Jude Care & Treatment

Menu

Close

Recruiting

DAPHNE: Dalbavancin to Prevent Infections in High-Risk Leukemia

About this study

Chemotherapy can severely weaken the immune systems of children and teens with acute myeloid leukemia (AML) or relapsed acute lymphoblastic leukemia (ALL). So, they are more likely to get serious infections. These infections can make it hard to recover from cancer. We want to find better ways to protect these patients from infections during treatment.

In this study, we are testing a medicine called dalbavancin. This antibiotic stays in the body for a long time. So, it only needs to be given once every 28 days. Dalbavancin will be given along with another antibiotic, either ciprofloxacin or levofloxacin. They are commonly used antibiotics. The goal is to see if this combination can prevent infections better than the usual treatments.

Patients may get up to 3 doses of dalbavancin over 12 weeks. We will collect samples and watch patients to see how well the medicine works and if there are any side effects. We will also compare the results to past patients who got different treatments to see if dalbavancin is more effective.

This study is important because it could lead to better ways to protect young cancer patients from infections. If dalbavancin works well, it might become a new standard treatment. This update would make cancer therapy safer and more comfortable for children and teens. 

Eligibility overview

  • Acute myeloid leukemia
  • Relapsed acute lymphoblastic leukemia
  • Up to age 25
  • Currently or expected to receive chemotherapy for their disease

Request a referral

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

A Prospective, Single-Arm, Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents with High-Risk Leukemia

Study goal:

To study dalbavancin for infection prevention in children and teens with acute myeloid leukemia or relapsed acute lymphoblastic leukemia.

Diagnosis:

Acute myeloid leukemia, Acute lympoblastic leukemia

Age:

Up to age 25

Clinical trials categories:

Infectious Diseases Acute Myeloid Leukemia (AML) Childhood Cancer Leukemia Acute Lymphoblastic Leukemia (ALL)

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more